The Management of Monochorionic-Diamniotic Twins

Similar documents
Non-Invasive Prenatal Testing (NIPT) Factsheet

The California Prenatal Screening Program

First Trimester Screening for Down Syndrome

LEUKODYSTROPHY GENETICS AND REPRODUCTIVE OPTIONS FOR AFFECTED FAMILIES. Leila Jamal, ScM Kennedy Krieger Institute, Baltimore MD

Prenatal screening and diagnostic tests

Obstetrical Ultrasound and Prenatal Diagnostic Center

Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free β-hcg and PAPP-A at to13+ 6 weeks

Clinical Studies Abstract Booklet

The weeks scan

fi АУ : fi apple Ав Ав АУ . apple, АУ fiав Ав. АК applefi АУ, АУАв Ав fi АУ apple fi Ав. А applefi АУ АУ АУ АсА» Ас Ам, длappleapple Ас...

your questions answered the reassurance of knowing A guide for parents-to-be on noninvasive prenatal testing.

Noninvasive Prenatal Screening for Fetal Aneuploidies and Microdeletions Using Cell-Free Fetal DNA

Neural tube defects: open spina bifida (also called spina bifida cystica)

cfdna in maternal plasma obtained from a population undergoing routine screening at weeks gestation.

Sonographic screening for trisomy 13 at 11 to 13 D6 weeks of gestation

Long-Term Prognosis of Pregnancies Complicated by Slow Embryonic Heart Rates in the Early First Trimester

Clinical Policy: Ultrasound in Pregnancy Reference Number: CP.MP.38

Noninvasive Prenatal Testing for Fetal Aneuploidies Using Cell- Free Fetal DNA

A test your patients can trust.

The National Down Syndrome Cytogenetic Register for England and Wales: 2008/9 Annual Report

Prenatal Testing Special tests for your baby during pregnancy

CONFIDENT CODING FOR OB/GYN CONFIDENT CODING FOR OB/GYN

Choosing Wisely. Obstetrics / Maternal Fetal Medicine Things Providers and Patients Should Question

Trisomies 13 and 18. -Maternal age. (Patau and Edward s syndrome)

Gutenberg Center in MALAGA

Patient information on soft markers

SWISS SOCIETY OF NEONATOLOGY. Umbilical cord complications in two subsequent pregnancies

Sequencing-based Tests to Determine Trisomy 21 from Maternal Plasma DNA

Charts of fetal size: limb bones

The California Prenatal Screening Program

Effect of Increased Body Mass Index on the Accuracy of Estimated Fetal Weight by Sonography in Twins

Knowledge and Perception of the Role of Targeted Ultrasound in Detecting Down Syndrome Among a High Risk Population

Clinical Significance of First Trimester Umbilical Cord Cysts

Fetal Prognosis in Varix of the Intrafetal Umbilical Vein

Screening for chromosomal abnormalities at weeks: the role of ductus venosus blood flow

The Mysterious World of OB Ultrasound Coding

Second-trimester maternal serum alpha-fetoprotein elevation and its association with adverse maternal/fetal outcome: ten years experience

Effect of incorrect gestational dating on Down s syndrome and neural tube risk assessment

Executive summary. Current prenatal screening

Down s Syndrome: Ultrasound Screening

Placenta, Cord, & Fluid

Position Statement from the Aneuploidy Screening Committee on Behalf of the Board of the International Society for Prenatal Diagnosis, April 2013

Aim of maternal-foetal care

Universal Fetal Cardiac Ultrasound At the Heart of Newborn Well-being

AUSTRALIA AND NEW ZEALAND FACTSHEET

Frontomaxillary and mandibulomaxillary facial angles at to13+ 6 weeks in fetuses with trisomy 18

Ultrasound evaluation of fetal gender at weeks

Data validation and Data sources

The First Trimester Screening program

The first 3,000 Non-Invasive Prenatal Tests (NIPT) with the Harmony test in Belgium and the Netherlands

BELIEVE MIDWIFERY SERVICES, LLC

Obstetrical Complications Associated With Abnormal Maternal Serum Markers Analytes

Embryonic Heart Rate as a Prognostic Factor for Chromosomal Abnormalities

Analytical goal setting in aneuploidy screening: within person biological variability of first trimester biochemical markers

Department of Obstetrics and Gynecology, Kayseri Military Hospital, Kayseri, Turkey

Prognosis of Very Large First-Trimester Hematomas

Evaluation and Follow-up of Fetal Hydronephrosis

SOFT FETAL ULTRASOUND FINDINGS

Ultrasonographic Diagnosis of Trisomy 18: Is It Practical in the Early Second Trimester?

Correspondence: Dr K. Spencer, Endocrine Unit, Clinical Biochemistry Department, Harold Wood Hospital, Gubbins Lane, Romford, Essex, RM3 0BE, UK

Risk Calculation Software Requirements for Down's Syndrome Screening

New Prenatal Tests for Down Syndrome: Brian G. Skotko, MD, MPP Co-Director, Down Syndrome Program Massachusetts General Hospital

The quadruple test screening for Down s syndrome and spina bifida

Assessment of Fetal Growth

Article. Anthony O. Odibo, MD, Christopher Riddick, Emmanuelle Pare, MD, David M. Stamilio, MD, MSCE, George A. Macones, MD, MSCE

Parvovirus B19 Infection in Pregnancy

A Guide to Prenatal Genetic Testing

Clinical Policy Title: Home uterine activity monitoring

Middle cerebral artery peak systolic velocity to predict fetal hemoglobin levels in twin anemia polycythemia sequence

COMMITTEE OPINION. Cell-free DNA Screening for Fetal Aneuploidy

The costs of having a baby. Private system

What women can do to optimise their health during pregnancy and that of their baby Claire Roberts

Weeks Scan Project Newsletter

Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies

Obstetrical Ultrasound Policy

First- and Second-Trimester Evaluation of Risk for Down Syndrome

CHROMOSOMES Dr. Fern Tsien, Dept. of Genetics, LSUHSC, NO, LA

Basic Human Genetics: Reproductive Health and Chromosome Abnormalities

Doppler Ultrasound in the Management of Fetal Growth Restriction Chukwuma I. Onyeije, M.D. Atlanta Perinatal Associates

Fetal Fraction Estimate in Twin Pregnancies Using Directed Cell-Free DNA Analysis

CONGENITAL HEART DISEASE

Birth defects. Report by the Secretariat

Neural Tube Defects - NTDs

Future. pathophysiology of preeclampsia. ? hypoxia. Also in. marker. 1st trim. In combi w PE s.flt-1 -- seng, PlGF, VEGF, US. Manifest.

The ultrasound detection of chromosomal anomalies 1

Epidemiology 521. Epidemiology of Maternal and Child Health Problems. Winter / Spring, 2010

Wendy Martinez, MPH, CPH County of San Diego, Maternal, Child & Adolescent Health

Multiple Pregnancy and Birth: Twins, Triplets, and High-order Multiples

Maternity Care Primary C-Section Rate Specifications 2014 (07/01/2013 to 06/30/2014 Dates of Service)

Transcription:

The Management of Monochorionic-Diamniotic Twins Part 2: Prenatal diagnosis and antenatal management Carla Ransom, MD Vanderbilt University November 30, 2012

none Disclosures

PRENATAL DIAGNOSIS & ANEUPLOIDY SCREENING IN TWINS

PRENATAL DIAGNOSIS IN MULTIPLE GESTATIONS Twins calculate the risk of aneuploidy by considering the maternal age related risk of aneuploidy, zygosity, and the probability that either one or both twins could be affected Discuss options for pregnancy management if one fetus is found to be affected (termination of entire pregnancy, selective termination, continuing the pregnancy)

INVASIVE TESTING IN TWINS Loss rate is ~3.5% when amnio is performed in twins (not higher then the background loss rate) small series No data on loss rates after amniocentesis in high-order multiple gestations Similar information exists in small nonrandomized series re CVS loss rates in twins

MONOCHORIONIC TWINS Likelihood of discordance in karyotype is low Both fetuses SHOULD be either affected or unaffected Exceptions possible Patients may opt for karyotype analysis on a single fetus Should discuss accuracy of chorionicity by ultrasound (most accurate at or before 14 weeks (98%))

Genetic Counseling Aneuploidy Singletons: age related Dizygotic twins Age related risk for anomalies is the same for each twin as for a singleton Monozygotic twins Should be age related risk

Advanced maternal age Singleton: age 35 at delivery Monochorionic twins: age 35 at delivery Dizygotic twins: Literature review: age 31-33 ACOG: age 33 Triplets, & high-order multiples:? Insurance? Obstet Gynecol 1997; 89:248-51 Semin Perinatol. 2005 Oct;29(5):312-20

Prenatal diagnosis options Screening tests First trimester screening Second trimester MSAFP only Second trimester ultrasound screening Multiple marker screening Invasive diagnostic tests Chorionic villi sampling Amniocentesis

First trimester NT screening Maternal age + NT screening Valid from 10 4/7 to 13 6/7 weeks. Sensitivity of NT alone in multiple gestations ranges from (68%-88%) Detection of Down s with multiples is similar to singletons Not affected by ART or number of multiples Sepulveda, Ultrasound Obstet Gyn 2008 Br J Obstet Gynaecol 1996; 103(10): 999-1003 DeVore, www.fetal.com

NT: Twin = Singleton Nuchal Translucency Mean mm Mean MOM (Mean CRL) N (+ SD) (+ SD) Singletons 1.5 0.9 120 (62.7 mm) (+ 0.5) (+ 0.5) Twins 1.5 0.9 120 (62.3 mm) (+ 0.17) (+ 0.4) P NS NS Maymon R et al. Prenat Diagn 1999; 19: 727-731

Down s Syndrome Screening Twins Analytes valid IUFD at >8 wks invalidates screening Higher order multiples NT measurements only

Nuchal Translucency Monochorionic Twins NT obtained individually and averaged to give risk to pregnancy. Concordant karyotype Discordant NT measurement False positive rate increased to 8% Thickened NT may be early TTTS

NT Images

Nuchal Translucency in Twins

First trimester combined screening Maternal age and NT + maternal serum free β- hcg and pregnancy associated plasma protein-a (PAPP-A) Twins: (5% false positive rate) Monochorionic: ~84% detection rate for DS Dichorionic: ~70% detection rate for DS

First trimester screening Pseudorisk approach: Larger of the two crown-rump lengths-ega Sum the two NT likelihood ratios multiplied by the biochemical likelihood ratio to get the pregnancy specific risk Sensitivity of 75-85% in twins False positive rate 5-9% Semin Perinatol 29: 395-400 Am J Obstet Gynecol. 2007 Oct;197(4):374.e1-3

First trimester combined screening Criticism: Abnormal serum levels from an affected fetus will bring overall serum levels closer to the mean by unaffected fetus Unknown effect of ART on first trimester serum markers Unclear on whether adding serum markers is superior to using NT alone Statistical modeling

Second trimester MSAFP Used to screen for ONTDs Can be used in twin gestations Less reliable than singletons Clin Perinatol 32 (2005): 443-454.

MOM ( X) Anencephaly (%) Detection rate Open spina bifida (%) False positive (%) 2.0 100 96 46 2.5 99 89 30 3.0 98 80 19 3.5 96 69 12 4.0 93 58 7.8 4.5 89 48 5.0 5.0 83 39 3.3 5.5 77 31 2.2 6.0 70 25 1.4 Wald NJ, Prenat Diagn 2005; 25: 740 745

Second trimester ultrasound Major structural abnormalities Soft markers (Likelihood ratio) Nuchal thickening (11) Echogenic bowel (6.7) Short humerus (5.1) Short feumr (1.5) Echogenic intracardiac focus (1.8) Pylectasis (1.5) Sandal gap deformity Absent nasal bone Absence may reduce DS risk 50% Clin Perinatol 32 (2005) 373 386 Nyberg J Ultrasound Med 2001;20(10):1053-63

Multiple marker screening Serum AFP, beta human chorionic gonatotropin (βhcg), unconjugated estriol, and inhibin-a Singletons: 77% detection rate, 5% false-positive Twins: 47% detection rate, 5% false-positive Problems: Normalization of serum values Which fetus is anomalous? Clin Perinatol 32 (2005) 373 386

Conflicting data: O Brien et. al. 4443 twin pregnancies compared to >250,000 singletons. Inconsistent results for the different analytes Garchet-Beaudron et. al. Prospective study of second-trimester maternal serum markers 11,040 twin & 64,815 singleton pregnancies Mean detection rate was 63% 74.4% in singletons. False-positive rates: 10.8% in twins vs 10.3% in singletons (NS). Am J Med Genet. 1997 Dec 12;73(2):109-12 Prenat Diagn. 2008 Nov 11;28(12):1105-1109

Live-Born Down Syndrome Prevalence Live-born twin Down syndrome (DS) prevalence only 18% higher than singletons. 1 Population-based study of 106 twin DS live births only 3% > singletons. 2 Wald et al. Fetal Diagnosis of Genetic Defects. Vol 1, #3. London; 1987:649-676 Doyle et al. Congenital malformations in twins, J Epid Comm Health 1990; 45:43-48.

Down Syndrome Detection Rate in Twins by Chorionicity at a 5% FPR Twin Pregnancy NT Alone (%) Combined Test (%) Integrated Test (%) Monochorionicdiamniotic Dichorionicdiamniotic 73 84 93 68 70 78 All twins 69 72 80 Singleton 73 85 95 Wald et al. Prenat Diagn 2003; 23:588-592

Invasive testing CVS Amniocentesis

CVS Sampling of chorionic villi for DNA or chromosome analysis Transcervical or transabdominal, under ultrasound guidance Done between 10-13 weeks van den Berg, Prenatal Diagnosis 1999: 19 Semin Perinatol 29:312-320 images.main.uab.edu/healthsys/ei_0096.jpg

CVS Advantages: Early detection Disadvantages More technically challenging than amniocentesis Risk of cross contamination/ incorrect sampling of up to 4% Semin Perinatol 2005: 29:312-320

Accuracy: CVS Appears to be accurate for diagnosis Some risk of indeterminate results from placental mosaicism Risks: Loss rates in twins reported range from 0-4.5% Recent studies on CVS and multiples: loss rates for CVS no different than amniocentesis Prenat Diagn 19:234-244, 1999 Semin Perinatol 29:312-320

Amniocentesis Transabdominal removal of amniotic fluid for genetic analysis 15-20 weeks van den Berg, Prenatal Diagnosis 1999: 19

Amniocentesis in multiples First described in twins in 1980 Described sampling clear fluid from first sac then adding indigo carmine Sampling of clear fluid from the second sac ensured adequate sampling from both Technique still useful with mono- or dichorionic twins, high-order multiples Mapping is key Semin Perinatol 29:312-320

Use of marker dye Methylene blue Fetal hemolysis Methemoglobinemia Multiple ileal obstruction Jejunal atresia Indigo carmine Not associated with abnormal fetal outcomes Obstet Gynecol 61:35S-37S,1983 Lancet 336:1258-1259, 1990 Obstet Gynaecol 99:89-90, 1992 Br J Obstet Gynaecol 99:141-143, 1992

Amniocentesis in multiples Loss rates in twins: Range from 2.5-3.5% following genetic amniocentesis Monochorionic twins Sample one or both? Semin Perinatol 2005 29:312-320

New Microarray technology Van den Veyver, et al: Baylor 300 cases Array comparative genomic hybridization Smaller deletions or duplications seen 58 copy number variations found 2 clinically significant Van den Veyver, Prenat Diag (2008), pub online 14 Nov 2008

Microarray- pitfalls Case reports of monochorionic (and monozygotic) twins with differing microdeletion sizes as detected by microarray Different phenotypes CAN be seen Microdeletions does not ALWAYS equal clinical syndrome

PRACTICAL ISSUES: ANTENATAL CARE

Maternal nutrition & weight gain Goals: 1. Optimize fetal growth 2. Reduce the incidence of obstetrical complications 3. Minimize risk preterm birth 4. Avoid excess weight gain

Gestational age Recommended rate of maternal weight gain for twins Underweight Normal weight Overweight Obese Early (<20 wk) 1.25-1.75 lb/wk 1-1.5 lb/wk 1-1.25 lb/wk 0.75-1 lb/wk Mid (21-28 wk) 1.5-1.75 lb/wk 1.25-1.75 lb/wk 1-1.5 lb/wk 0.75-1.25 lb/wk Late (>28 wk) 1.25 lb/wk 1 lb/wk 1 lb/wk 0.75 lb/wk Luke B. J Reprod Med 48:217, 2003.

Institute of Medicine weight gain guidelines Prepregnancy BMI BMI Singleton- total gain (lb) Twins- total gain (lb) underweight <18.5 28-40 None made normal 18.5 24.9 25-25 37-54 overweight 25.0 29.9 15-25 31-50 obese >30 11-20 25-42 Rasmussen KM: Institute of Medicine. Weight Gain During Pregnancy: Reexamining the Guidelines. Washington, DC, National Academy Press, 2009.

ANTENATAL TESTING

Surveillance for Fetal Well-Being Estimated fetal weight Amniotic fluid assessment Subjective assessment Maximum vertical pocket Umbilical cord Doppler velocimetry Only if underlying indication of FGR

Ultrasound Surveillance Monochorionic twins Ultrasound evaluation every 2 weeks beginning in the 2nd trimester Abnormal growth Amniotic fluid discordance Dichorionic twins Ultrasound every 4-6 weeks after 20 weeks gestation Optimal detection of fetal growth deceleration between 20 and 28 weeks of gestation Cervical length measurement up to 26-28 weeks

Surveillance for Fetal Well-Being: High Risk FGR, discordant growth, abnormal amniotic fluid volume, monoamnionicity, preeclampsia Uncomplicated MC/DA twins also at increased risk of in-utero death Consider antenatal testing twice a week Growth every 2-3 weeks

Surveillance for Fetal Well-Being: Low-Risk Routine use of antepartum testing in uncomplicated DC twins has been demonstrated to be beneficial in retrospective but not prospective studies NSTs or BPPs performed once or twice weekly may identify those fetuses that would benefit from early delivery ~ 32 wks MC twins ~ 34-36 wks DC twins

What is discordant growth? Weight larger twin weight smaller twin Weight larger twin 15-25%

TIMING OF DELIVERY

When should uncomplicated monochorionic twins be delivered?

Postdates Pregnancy in Twins Prospective risk of fetal & neonatal death intersects ~ 38-39 weeks in twins (Kahn et al, ObGyn 2003;102)

Fetal vs. Neonatal Deaths in Twins Kahn et al, Obstet Gynecol 2003;102

Postdates Pregnancy in Twins Prospective risk of fetal & neonatal death intersects ~ 38-39 weeks in twins (Kahn et al, ObGyn 2003;102) Study of multiple gestations (99.8% twins) risk of fetal & neonatal death were equivalent at 37 38 weeks (Sairam S et al, ObGyn 2002;100) Take home point: deliver at 38 weeks

The problem: these data do not address chorionicity!

Studies arguing for early delivery Trial 1 1000 twins (20% MC, 80% DC) MC twins: higher stillbirth rates than the DC twins (3.6% vs. 1.1%; P =.004) Trial 2 A retrospective analysis from the United Kingdom 151 uncomplicated monochorionic pregnancies Risk for unexpected stillbirth after 32 weeks was 4.3% (1 in 23) Lee at al, Obstet Gynecol, 2008 Barigye, PLoS Med 2005

Study arguing for later delivery Breathnach, Obstet Gynecol, 2012: Prospective ESPIRiT study, Twins, Ireland N = 1001 pregnancies (20 % MC, 80% DC) Prospective risk fetal death: 1.5% after 34 weeks for MC, Compositive morbidity: 41% at 34 weeks vs 5% at 37 weeks. Consider delivery at 37 weeks for MC.

Take home: delivery for monochroinic twins Delivery of uncomplicated monochorionic, diamniotic twins- between 34 and 38 weeks More research desperately needed!

SUMMARY OF RECOMMENDATIONS DIAGNOSIS- chorionicity matters! NUTRITION- follow weight gain goals REFERRAL TO MFM- for any high risk developments ANTENATAL TESTING Q 2 week screen for TTTS Monthly growth Twice weekly antenatal at 32-34 weeks DELIVERY- between 34-38 weeks if uncomplicated

Thank you!